对比分析贝那鲁肽/利拉鲁肽对2型糖尿病患者长期结局的影响  

Comparative analysis of the long-term outcome of the patients with type 2 diabetes mellitus treated with the treatment of the patients with type Ⅱ diabetes

作　　者：史丽[1] 胡婷婷[1] 李红 张三明[1] 刘智慧 左惠玲 胡利梅[1] 任卫东[1] Shi Li;Hu Ting-ting;Li Hong;Zhang San-ming;Liu Zhi-hui;Zuo Hui-ling;Hu Li-mei;Ren Wei-dong(The First Affiliated of Hebei North University,Zhangjiakou 075000,China;Zhangjiakou Health Committee,Zhangjiakou 075000,China)

机构地区：[1]河北北方学院附属第一医院,张家口075000 [2]张家口市卫生健康委员会,张家口075000

出　　处：《湖南师范大学学报（医学版）》2022年第1期40-43,共4页Journal of Hunan Normal University(Medical Sciences)

基　　金：张家口市科技攻关计划项目(2021040D);2021年度河北省“三三三人才工程”资助项目(A202103006)。

摘　　要：目的:对比分析贝那鲁肽/利拉鲁肽对2型糖尿病患者长期结局的影响,为二甲双胍和磺脲类药物治疗后血糖不能达标的患者应用GLP-1受体激动剂提供临床依据。方法:选取2018年3月~2019年3月在我院就诊的使用二甲双胍或者二甲双胍联合磺脲类药物血糖未达标的2型糖尿病患者150例作为研究对象。随机分为观察组和对照组,随机方式为随机数字表法,每组各75例。观察组使用贝那鲁肽注射液治疗,对照组使用利拉鲁肽注射液治疗,所有患者均连续治疗24周。比较两组患者治疗前后FPG、餐后2h血糖(2hPG)、HbA1c、收缩期血管峰值血流(PSV)、血管内膜中层厚度(IMT)、肌酐(Scr)和尿素氮(BUN)水平,两年内的不良事件发生率、心血管相关死亡率和全因死亡率。结果:两组患者之间治疗前、后FPG、2hPG、HbA1c、PSV、IMT、Scr和BUN水平无统计差异,观察组的不良事件总发生率(8%)低于对照组(20%),且差异具有统计学意义,两组患者心血管相关死亡率和全因死亡率相比,差异无统计学意义。结论:在使用二甲双胍或者二甲双胍联合磺脲类药物血糖未达标的2型糖尿病患者中,与利拉鲁肽相比,贝那鲁肽在降低血糖、改善下肢血管功能、肾功能和死亡率方面无明显差异,但不良事件发生率更低。Objective To compare and analyze the effects of the 2 patients with type 2 diabetes mellitus (PDM) on the long-term outcome of the patients,and to provide clinical evidence for the use of GLP-1 receptor agonists in the patients who failed to reach the standard after the treatment of metformin and sulfonylureas.Methods From March 2018 to March 2019,150 patients with type 2 diabetes who were treated with metformin or metformin combined with sulfonylureas were still not up to standard.They were randomly divided into observation group and control group.The observation group was treated with benalutide injection and the control group was treated with liraglutide injection.All patients were treated for 24 weeks.The random method was random number table,with 75 cases in each group.The levels of FPG,2h postprandial blood glucose (2hPG),HbA1c,peak systolic blood flow (PSV),intima-media thickness (IMT),creatinine (SCR) and urea nitrogen (BUN) before and after treatment,the incidence of adverse events,cardiovascular related mortality and all-cause mortality within two years were compared between the two groups.Results There was no significant difference in the levels of FPG,2hPG,HbA1c,PSV,IMT,SCR and BUN between the two groups before and after treatment.The total incidence of adverse events in the observation group (8%) was lower than that in the control group (20%),and the difference was statistically significant.There was no significant difference in cardiovascular related mortality and all-cause mortality between the two groups.Conclusion In type 2 diabetic patients with metformin or metformin combined with sulfonylureas,Benner Lou has no significant difference in lowering blood sugar,improving blood vessel function,renal function and mortality,but has a lower incidence of adverse events.

关 键 词：2型糖尿病 利拉鲁肽 贝那鲁肽 死亡 

分 类 号：R587.1[医药卫生—内分泌]